Chair, Chemistry and Chemical Biology, Northeastern University
Pharmaceutical and biotech development of cannabinoid-based drugs has recently become a highly active and fertile ground for the generation of a new class of regulated therapeutics. The combination of advancements in our understanding the underlying biology of the endocannabinoid system, with the production of natural and synthetic cannabinoid products, is now being shown to have myriad therapeutic value for unmet medical conditions. The inaugural International Cannabinoid-Based Drug Discovery and Development (iCBD3) Congress, co-located with the 8th Plant Genomics and Gene Editing Congress, March 4-5 in Rotterdam, Netherlands will explore an array of drug targets, therapies, manufacturing processes, regulatory frameworks, clinical studies and market opportunities for cannabinoid-based pharmaceuticals.
This programme creates a collaborative environment in which you can create enduring relationships across the full range of cannabinoid pharmaceutical discovery and development.
In a preview of his presentation hear Jeremy Friedberg, CSO of LAVVAN discuss the advantages biosynthesis of cannabinoids has over traditional cultivation and the challenges this presents.
Track One: Cannabinoid Research and Discovery
Genomics, molecular biology and target validation in disease
Medicinal chemistry, pharmacology and biosynthesis
Track Two: Cannabinoid Development and Manufacturing
Regulatory standards, clinical studies and opportunities in primary markets
Bioprocessing, analytics and manufacturing